CoChat

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

Open access

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Abstract

Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6Clo monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the chemokine CX3CL1 was upregulated in both human and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1+Ly6Clo monocytes into the tumor. We also found that treatment with VEGFA reduced expression of CX3CL1 in endothelial cells in vitro. Intravital microscopy revealed that CX3CR1 is critical for Ly6Clo monocyte transmigration across the endothelium in murine CRC tumors. Moreover, Ly6Clo monocytes recruit Ly6G+ neutrophils via CXCL5 and produce IL-10, which inhibits adaptive immunity. Preventing Ly6Clo monocyte or Ly6G+ neutrophil infiltration into tumors enhanced inhibition of tumor growth with anti-VEGFR2 therapy. Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6Clo monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs. Our study unveils an immunosuppressive function of Ly6Clo monocytes that, to our knowledge, has yet to be reported in any context. We also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potential immunomodulatory strategies to enhance the long-term clinical outcome of anti-VEGF therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci93182

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

Metadata

Authors
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., Yun, S. H., Langer, R., Anderson, D. G., Padera, T. P., Jain, R. K., & Fukumura, D.
Affiliations
  • Harvard University (US)
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Duke Medical Center (US)
  • Harvard–MIT Division of Health Sciences and Technology (US)
Venue
Journal of Clinical Investigation
Published
2017-07-10
Volume
127
Issue
8
Pages
3039-3051
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2726768474
Cited by
164
References
75
Citations by year
2026: 10 · 2025: 10 · 2024: 13 · 2023: 10 · 2022: 28 · 2021: 26 · 2020: 25 · 2019: 20 · 2018: 16 · 2017: 6
FWCI
8.29
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (W81XWH1010016, W81XWH)
  • National Institutes of Health (NIH DP2, W81XWH, 1dp2od008780-01, CA126642, CA080124)
  • Harvard School of Engineering and Applied Sciences
  • National Cancer Institute (CA096915, W81XWH-10-1-0016, R01CA096915, P01CA080124, R00CA137167, R01CA126642, R35CA197743, R01CA208205, R01CA204028)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
fractalkine, CX3CR1, anti-VEGF therapy resistance, colorectal cancer, immunosuppression, neutrophil recruitment, CXCL5, IL-10, endothelial cells, monocyte transmigration, siRNA gene therapy, nanoparticle delivery, tumor microenvironment
MeSH terms
Intravital Microscopy, CX3C Chemokine Receptor 1, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Agents, Humans, Immunosuppression Therapy, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Monocytes, Neoplasms, Neutrophils, Up-Regulation, Drug Resistance, Neoplasm, Receptors, Chemokine, RNA, Small Interfering, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, Mice, Nanoparticles, Chemokine CX3CL1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.